Cargando…
Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio
The use of immune checkpoint inhibitors (ICIs) has provided overall survival (OS) benefits in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. However, studies comparing ICIs monotherapy with combination therapy either with chemotherapy o...
Autores principales: | Tsai, Jeng-Shiuan, Wei, Sheng-Huan, Chen, Chian-Wei, Yang, Szu-Chun, Tseng, Yau-Lin, Su, Po-Lan, Lin, Chien-Chung, Su, Wu-Chou |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694359/ https://www.ncbi.nlm.nih.gov/pubmed/36422537 http://dx.doi.org/10.3390/ph15111407 |
Ejemplares similares
-
Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
por: Chen, Chian-Wei, et al.
Publicado: (2023) -
Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs
por: Chu, Chang-Yao, et al.
Publicado: (2023) -
Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
por: Su, Po‐Lan, et al.
Publicado: (2019) -
Navigating the challenges of invasive pulmonary aspergillosis in lung cancer treatment: a propensity score study
por: Kuo, Chin-Wei, et al.
Publicado: (2023) -
The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis
por: Chang, Wei-Yuan, et al.
Publicado: (2018)